Neuroblastoma (NB) is a rare but aggressive pediatric cancer, the third most-common in children and the most frequent in babies. Researchers from the U.S. National Cancer Institute and collaborators have reported findings from their study investigating the use of [67Cu]Cu-LLP2A as radiopharmaceutical therapy before CAR T-cell treatment in preclinical models of NB.
Resistance to microtubule-targeting agents such as taxanes and vinca alkaloids is often driven by drug efflux and changes in tubulin behavior. Targeting the colchicine-binding site provides an alternative strategy that may circumvent these resistance mechanisms.
Neuroblastoma cells harbor a pattern of chromosomal aberrations that include chromosomes 1p and 11q deletions and 2p and 17q gains, as well as MYCN gene amplification with MYC overexpression. Recent research has identified RuvB-like 1 (RUVBL1) and RUVBL2 to be key mediators of the therapeutic response to a promising strategy such as serine/threonine-protein kinase ATR inhibition.
A recent study assessed the applicability of McERV-pseudotyped lentiviral vector particles (McERV-PTLVs) to target cancer cells of glial or neuronal origin.
Australian researchers have found a drug combination that can bypass the cellular defenses in neuroblastoma that lead to relapse, and the discovery could lead to better treatment strategies for children whose cancers have stopped responding to standard chemotherapy.
Neuroblastoma is a pediatric extracranial solid tumor arising from the sympathetic nervous system. Disialoganglioside GD2-based therapies, including CAR T cells and other immunotherapies, have shown some success. However, GD2 is also expressed on pain fibers and other neurons, raising safety concerns, and relapses after anti-GD2 therapy are frequent.
Australian researchers have found a drug combination that can bypass the cellular defenses in neuroblastoma that lead to relapse, and the discovery could lead to better treatment strategies for children whose cancers have stopped responding to standard chemotherapy.
Myrio Therapeutics Pty Ltd. has been able to accomplish something no other company has yet been able to crack: to develop binders where both the affinity and the specificity can be increased.
Myrio Therapeutics Pty Ltd. has been able to accomplish something no other company has yet been able to crack: to develop binders where both the affinity and the specificity can be increased.
Myrio Therapeutics Pty Ltd. has been able to accomplish something no other company has yet been able to crack: to develop binders where both the affinity and the specificity can be increased.
